ArticleFrontiers in oncology2025
Trifluridine- and tipiracil-induced DPD inhibition mimicking DPD deficiency: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluoropyrimidines, including 5-fluorouracil (5-FU) and its derivatives, remain the standard first-line treatment for metastatic colorectal cancer (mCRC). In recent years, trifluridine/tipiracil (TAS-102), an orally administered combination drug, has become a common third-line therapy for mCRC and could increasingly be used as first-line treatment. We report, for the first time, the case of an mCRC patient presenting discrepancies in uracilemia between measurements taken during (43.0 µg/L) and outside trifluridine/tipiracil treatment (7.3 and 4.5 µg/L). This inconsistency could be attributed to the metabolism of trifluridine into 5-carboxyuracil (5-CU), which can interfere with dihydropyrimidine dehydrogenase (DPD) phenotyping and cause falsely elevated uracilemia. This can lead to unnecessary reduction in the dose of fluoropyrimidines. Clinicians should be aware of this potential interaction when performing DPD phenotyping in patients treated with trifluridine/tipiracil, ensuring that testing is performed either before the treatment begins or after it has finished, or when genotyping
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.